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Abstract
Recent discovery of nusinersen, an antisense oligonucleotide drug, has provided encouragement for improving treatment of 
spinal muscular atrophy. No therapeutic options currently exist for this autosomal recessive motor neuron disorder. Nusin-
ersen is developed for intrathecal use and binds to a specific sequence within the survival motor neuron 2 pre-messenger 
RNA, modifying the splicing process to promote expression of full-length survival motor neuron protein. We performed a 
MEDLINE and CENTRAL search to investigate the current evidence for treatment with nusinersen in patients with spinal 
muscular atrophy. Four papers were withheld, including two phase-3 randomized controlled trials, one phase-2 open-label 
clinical trial and one phase-1 open-label clinical trial. Outcome measures concerned improvement in motor function and 
milestones, as well as event-free survival and survival. Results of these trials are hopeful with significant and clinically 
meaningful improvement due to treatment with intrathecal nusinersen in patients with early- and later-onset spinal muscular 
atrophy, although this does not restore age-appropriate function. Intrathecal nusinersen has acceptable safety and tolerability. 
Further trials regarding long-term effects and safety aspects as well as trials including broader spinal muscular atrophy and 
age categories are required and ongoing.
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Introduction
Spinal muscular atrophies (SMA) form a phenotypically 
heterogeneous spectrum and are progressive, hereditary, 
autosomal recessive disorders of anterior horn cells and 
selective motor cranial nerve nuclei [1]. Incidence is about 
1/11,000 live births. The disease is caused by loss of func-
tion of both alleles of the survival of motor neuron (SMN) 
1 gene resulting in decreased expression of SMN protein 
causing degeneration of motor neurons. In 95% of cases, 
a homozygous deletion is observed [2]. The SMN2 gene 
also encodes for SMN protein but differs by 11 nucleotides 
from SMN1 resulting in skipping of exon 7 in about 90% of 
the mature RNA transcripts and production of a truncated, 
non-functional protein [1–3]. The SMA phenotype is related 
to the copy number of the SMN2 gene [1]. Nusinersen, an 
antisense oligonucleotide drug, can be injected intrathe-
cally in order to enhance expression of the SMN protein 
through targeting a heterogeneous nuclear ribonucleopro-
tein A1-dependent splicing silencer in intron 7 of the SMN 
pre-messenger RNA leading to increased synthesis of tran-
scripts containing exon 7 [4]. Careful optimism concerning 
treatment for SMA exists. We wanted to verify the current 
evidence of efficacy concerning improvements in motor 
function, achieving motor milestones (MM) and survival 
of intrathecal administration of nusinersen in SMA patients 
versus standard medical care.
Materials and methods
Search strategy
The first author performed after determining the search pro-
tocol a MEDLINE and CENTRAL search on December 21, 
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2018, respectively, via PubMed using search terms ‘Muscu-
lar Atrophy, Spinal’ as medical subject headings and ‘nusin-
ersen’ or ‘Spinraza’ as text words and via the Cochrane 
Library using search terms ‘spinal muscular atrophy’ and 
‘nusinersen’ as text words. The selected time period was 
unrestricted. The retrieved articles were examined for useful 
references. In order to update our search, a second search 
was performed on April 22, 2019, using the same protocol.
Selection
Only original articles evaluating the efficacy of intrathecal 
nusinersen in SMA patients were included. The interven-
tions and outcome measures had to be clearly defined.
Outcome reporting
We intended to address outcome measurements concern-
ing improvements in motor function, achieving MM and 
survival.
Evidence grading
The selected articles were assessed by the first author, and 
the findings of the studies were extracted and summarized. 
The quality of the studies was appraised according to the 
classification levels of evidence using the Evidence-Based 
Guideline Development (EBRO) classification of the Dutch 
Cochrane Centre [5]. Level of evidence was also consid-
ered based on the EBRO and Oxford 2009 [6] level of 
evidence criteria and the American Academy of Neurol-
ogy (AAN) classification of evidence matrix [7]. Grade of 
recommendation was based on the Oxford 2009 criteria, and 
quality was interpreted using the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) 
discriminatory instrument [8].
Results
An overview of the literature search is shown in Fig. 1. 
Twenty and 17 references were found via MEDLINE and 
CENTRAL, respectively, on December 21, 2018. Two trial 
registrations [9, 10], nine conference abstracts [11–19] and 
one conference review [20] were excluded. Three articles 
were found via MEDLINE and CENTRAL [1–3]. One 
reference concerned the same article [2]. Of the remain-
ing, six reviews mentioned information on included papers 
[21–26] and ten articles were not focused on the predefined 
outcome measures [27–36], of which one also was found 
in both databases [36]. Finally, four studies remained, of 
which two had more than 120 subjects, both two phase-3 
randomized controlled trials (RCTs) [1, 2] and two stud-
ies of 20–28 subjects, a phase-2 open-label clinical trial [3] 
and a phase-1 open-label clinical trial [4]. No additional 
papers were included after the second search, as shown in 
supplementary Fig. S1. A summary of the selected articles 
is given in Table 1, and baseline characteristics of the sub-
jects are shown in supplementary table S1. Data on principal 
inclusion and exclusion criteria are given in supplementary 
table S2. No additional papers were identified through refer-
ence lists. A list of all screened, but excluded references is 
available in the supplementary appendix. Quality and evi-
dence levels are depicted in Table 2, and throughout the text 
Fig. 1  Search strategy and outcome. *Additional filters: 1. Lan-
guages: English. 2. Article types: Case reports, Clinical Trial, Con-
trolled Clinical Trial, Multicenter Study, Randomized Controlled 
Trial, Review and Systematic Reviews. CENTRAL Cochrane Central 
Register of Controlled Trials, MEDLINE Medical Literature Analysis 
and Retrieval System Online, Mesh medical subject headings, Tw text 
word
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Table 2  Statements, recommendations, evidence and quality appraisal
Author, year Quality 
of study 
EBRO
Classification of 
evidence AAN 
(Class)
Level of evidence 
of conclusion 
EBRO
Level of evi-
dence Oxford 
(2009)
Grade of recom-
mendation Oxford 
(2009)
Quality of 
evidence 
GRADE
A. Statements per article
 Motor function and motor-milestone development
  1. There is a significant and meaningful change from baseline in HFMSE score with improvement in children with later-onset SMA treated 
with intrathecal nusinersen 12 mg
   Mercuri et al. 2018 [1] A2 I 2 1b – Moderate
  2. There is a significant increase in the amount of children with later-onset SMA, treated with intrathecal nusinersen 12 mg, who have an 
improvement of ≥ 3 points in HFMSE score
   Mercuri et al. 2018 [1] A2 I 2 1b – Moderate
  3. There is no significant increase in the amount of children with later-onset SMA, treated with intrathecal nusinersen 12 mg, who 
achieve ≥ 1 new WHO motor milestone
   Mercuri et al. 2018 [1] A2 IIb 2 1b− – Moderate
  4. There is a significant increase in the amount of infants with early-onset SMA treated with intrathecal nusinersen 12 mg EqD, who have a 
motor-milestone response according to HINE-2
   Finkel et al. 2017 [2] A2 I 2 1b? – High
  5. There is a significant increase in the amount of infants with early-onset SMA treated with intrathecal nusinersen 12 mg EqD, who have 
an improvement of ≥ 4 points on CHOP-INTEND score
   Finkel et al. 2017 [2] A2 I 2 1b? – Moderate
  6. There is a significant change in the amount of infants with early-onset SMA, treated with intrathecal nusinersen 12 mg EqD or the com-
bination of infants treated with 6-12 mg EqD and 12 mg nusinersen EqD, with improvement in HINE-2 score
   Finkel et al. 2016 [3] B III 3 3b – Very low
  7. There is a significant increase in CHOP-INTEND score in infants with early-onset SMA, treated with intrathecal nusinersen 12 mg EqD 
or the combination of infants treated with 6-12 mg EqD and 12 mg nusinersen EqD
   Finkel et al. 2016 [3] B III 3 3b – Very low
  8. There is a significant improvement in HFMSE score in children with later-onset SMA treated with a single dose of intrathecal nusinersen 
9 mg
   Chiriboga et al. 2016 [4] C IV 3 4 – Very low
 Survival
  9. There is a significant increase in event-free survival in the amount of infants with early-onset SMA treated with intrathecal nusinersen
   Finkel et al. 2017 [2] A2 I 2 1b− – Moderate
  10. There is a significant increase in survival in the amount of infants with early-onset SMA treated with intrathecal nusinersen
   Finkel et al. 2017 [2] A2 I 2 1b− – Moderate
  11. There is no significant increase in the amount of infants with early-onset SMA treated with intrathecal nusinersen who have no perma-
nent assisted ventilation
   Finkel et al. 2017 [2] A2 I 2 1b− – Moderate
  12. Compared to a historical cohort [37], in infants with early-onset SMA, there is a significant increase in median age at death or perma-
nent ventilation favoring treatment with intrathecal nusinersen (combination of infants treated wiht 6-12 mg EqD and 12 mg EqD)
   Finkel et al. 2016 [3] B III 3 3b – Very low
B. Overall statements
 Motor function and motor-milestone development
  1. Significant and meaningful improvement in motor function and achievement of development of motor milestones are seen in infants with 
SMA type 1 treated with intrathecal nusinersen 12 mg EqD
   Finkel et al. 2017 [2]
   Finkel et al. 2016 [3]
A2
C
I 2 1b? NAa High
  2. Significant and meaningful improvement in motor function and achievement of development of motor milestones is seen in children with 
later-onset SMA treated with intrathecal nusinersen 12 mg
   Mercuri et al. 2018 [1]
   Chiriboga et al. 2016 [4]
A2
C
I 2 1b NAa Moderate
 Survival
  3. Survival and event-free survival are significantly increased in infants with SMA type 1 treated with intrathecal nusinersen 12 mg EqD
   Finkel et al. 2017 [2]
   Finkel et al. 2016 [3]
A2
C
I 2 1b− NAa Moderate
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we show them together with the results as (AAN level of 
evidence, quality of evidence). Considerations for rating evi-
dence along the GRADE tool are shown in supplementary 
table S3. All papers reported to receive funding for the con-
ducted study and stated as conflicts of interest, for example, 
that the authors received grants, personal fees, held stock, 
were employees of the sponsor, but none of these are judged 
to be a major confounder.
Trial design
CHERISH TRIAL [1]—is a multicenter randomized, dou-
ble-blind, sham-procedure-controlled phase-3 study that 
tested the clinical efficacy, safety, tolerability and phar-
macokinetics of intrathecal nusinersen over 15 months in 
patients with later-onset SMA. There was actually a quad-
ruple masking of the participants, care providers, investiga-
tor and outcome assessor. Sham kits for performing lumbar 
puncture by an unblinded dedicated personnel, who did 
otherwise not participate in the trial, were provided. Only 
patients with documented SMN1 mutations with onset of 
symptoms above the age of 6 months old, age 2–12 years 
old at screening, who could sit independently but had never 
reached the ability to walk independently and Hammer-
smith Functional Motor Scale-Expanded (HFMSE) ranging 
10–54, were included. Patients were randomized in a 2:1 
ratio to receive a dose of 12 mg intrathecal nusinersen or a 
sham-procedure four times over 15 months. Randomization 
was stratified according to age at screening (< 6 years vs. 
≥ 6 years). A total of 126 patients were randomized, 84 in 
the intervention group, 42 in the control group.
ENDEAR TRIAL [2]—is a multicenter randomized, 
double-blind, sham-procedure-controlled phase-3 study that 
tested clinical efficacy, safety, tolerability and pharmacoki-
netics of intrathecal nusinersen over 13 months in patients 
with infantile-onset SMA. As in the CHERISH trial, there 
was a quadruple masking and a similar sham-procedure 
was used. Only patients with genetic documentation of 
SMA and SMN2 copy number of 2 with onset of symp-
toms after 1 week, but before 6 months and age less than 
7 months at screening were included. Patients were rand-
omized in a 2:1 ratio to receive an equivalent dose (EqD) of 
12 mg intrathecal nusinersen or a sham-procedure six times. 
Randomization was stratified according to disease duration 
(≤ 12 weeks vs. > 12 weeks). A total of 121 patients were 
randomized, 80 in the intervention group, 41 in the control 
group.
Finkel et al. TRIAL [3]—is a multicenter open-label, 
dose-escalation phase-2 trial that tested the clinical efficacy 
of multiple doses of nusinersen (6 mg and 12 mg dose equiv-
alents), safety, tolerability and pharmacokinetics of intrathe-
cal nusinersen in patients with infantile-onset SMA. Only 
patients with genetic documentation of SMA with onset of 
symptoms between 3 weeks and 6 months were included. 
Twenty patients were selected. Four patients received an 
EqD of 6 mg intrathecal each three times over a 3-month 
‘loading dose’ period and further in the maintenance dose 
period an EqD of 12 mg intrathecal every 4 months starting 
from about 8 months. Sixteen patients received an EqD of 
12 mg intrathecal each time following the same schedule. 
Interim results were reported in the study which was about 
18 months since the last subject was enrolled with follow-
up ranging 9–32 months and 2–27 months in, respectively, 
the 6–12 mg group and 12 mg group. The intended follow-
up stated in the trial protocol was about 45 months. Some 
reported outcomes were compared to subjects from a histori-
cal cohort [37].
Chiriboga et al. (2016) TRIAL [4]—is a multicenter 
open-label ascending single-dose phase-1 trial that tested 
the preliminary clinical efficacy, safety, tolerability and 
pharmacokinetics of intrathecal nusinersen in patients with 
later-onset SMA. Data included in the report are baseline 
evaluations for a follow-up study. Only patients with genetic 
documentation of SMA with age at screening between 2 
and 14 years old were included. Twenty-eight patients were 
selected. Nusinersen 1 mg, 3 mg and 6 mg was adminis-
trated to six patients each time, and ten patients received 
nusinersen 9 mg.
Motor function and motor milestones
All of the reports evaluated the achievement of motor func-
tion and MM development [1–4]. Two of these studies could 
be classified as methodological quality level A2 [1, 2].
In the CHERISH trial, a pre-specified interim analysis of 
the primary endpoint was conducted when all children had 
Table 2  (continued)
AAN American Academy of Neurology, CHOP-INTEND Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders score, 
EBRO Evidence-Based Guideline Development, GRADE Grading of Recommendations Assessment, Development and Evaluation, EqD equiva-
lent dose, HFMSE Hammersmith Functional Motor Scale-Expanded, HINE-2 Section 2 on Hammersmith Infant Neurological Examination, m 
month, NA not applicable, SMA spinal muscular atrophy, WHO World Health Organization
1b−: randomized controlled trial with wide confidence interval for the result
1b?: no confidence interval given in the randomized controlled trial for the result
a Because only single studies of the same evidence level were found, measuring the grade of recommendation was not applicable
b Results of < 80% of patients
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been enrolled for at least 6 months and at least 39 children 
had completed their 15-month assessment with the use of a 
multiple-imputation method to account for missing data. In 
this interim analysis, concerning 54 subjects with observed 
data, 35 and 19 in the intervention and control group, respec-
tively, and 72 children with imputed data, respectively, 49 and 
23, there was a least-squares mean increase from baseline in 
HFMSE in the intervention group (+ 4.0 points) and a least-
squares mean decrease in the control group (− 1.9 points). 
The significant between-group difference favoring nusinersen 
(least-squares mean difference in change 5.9 points; 95% 
confidence interval (CI) 3.7–8.1; P < 0.001) prompted early 
termination of the trial (I, moderate). In the final analysis, 
also a significant difference in the proportion of subjects who 
achieved a 3-point or greater increase from baseline in HFMSE 
was shown (I, moderate). More than half of the patients in 
the treatment group had a clinically meaningful increase in 
HFMSE score of at least three points with greatest improve-
ments in younger children and those who received treatment 
early. There was a non-significant difference in the achieve-
ment of new World Health Organization (WHO) MM (II, 
moderate) [1].
In the ENDEAR trial, a pre-specified interim analysis of 
the primary endpoint ‘MM response’ according to Section 2 
on Hammersmith Infant Neurological Examination (HINE-
2) score was conducted when approximately 80 infants had 
been enrolled for at least 6 months. In this analysis, concerning 
78 subjects, 51 and 27 in the intervention and control group, 
respectively, a significantly higher percentage of infants in the 
nusinersen group had a MM response (41% vs. 0%, P < 0.001) 
(I, high) which prompted early termination of the trial. In the 
final analysis, one secondary endpoint significantly favored 
nusinersen, namely response on Children’s Hospital of Phila-
delphia Infant Test of Neuromuscular Disorders (CHOP-
INTEND) score (71% vs. 3%, P < 0.001) (I, moderate) [2].
In Finkel et al., a significant change in HINE-2 score 
for both cohorts combined and in the 12 mg group was 
described, P = 0.0002 and P < 0.0001, respectively (III, very 
low). CHOP-INTEND score showed a mean increase of 11.5 
points (III, very low) [3]. The historical cohort [37] revealed 
a mean decline of 1.27 points per year from baseline (95% 
CI 0.21–2.33; P = 0.02) [3].
In Chiriboga et al. (2016), a significant improvement in 
HFMSE in the 9 mg group at 85 days and at 9–14 months 
was noticed with mean increase in HFMSE + 3.1 points or 
+ 17.6% (P = 0.016) and + 5.8 points or + 32.8% (P = 0.008) 
(IV, very low) [4].
Survival
Two studies assessed survival outcome measurements [2, 
3], one of which was classified as methodological quality 
level A2 [2].
In the ENDEAR TRIAL, in the final analysis the primary 
endpoint ‘event-free survival’ was significantly better for the 
intervention group [61% vs. 32%; Hazard Ratio 0.53 (95% 
CI) 0.32–0.89; P = 0.005] (I, moderate). This was most pro-
nounced among infants with a disease duration at screening no 
longer than the median duration of 13.1 weeks, and a signifi-
cantly lower percentage of infants in the treatment group had 
died. The secondary endpoint ‘survival’ was also significantly 
favoring nusinersen [84% vs. 61%; Hazard ratio 0.37 (95% 
CI) 0.18–0.77; P = 0.004] (I, moderate). The secondary end-
point ‘permanent ventilation’ was not significantly different 
among patients treated with nusinersen and the control group 
(I, moderate) [2].
In Finkel et al., median age at death or to permanent ven-
tilation was not reached. A differentiation in age at death or 
permanent ventilation was calculated by comparing infants 
with two copies of SMN2 (n = 17) to infants with two copies 
from the historical cohort [37] and was significant (P = 0.0014) 
(III, very low) [3].
Safety
The two RCTs conducted safety analysis in all patients who 
had been randomized and underwent at least one study pro-
cedure. None of the RCTs reported new safety concerns. The 
Fig. 2  Risk of bias summary
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overall incidence of adverse events (AEs) and type of AEs 
were similar in the treatment and control group. The majority 
of AEs were deemed unlikely or not related to study treat-
ment and could be explained by another cause such as SMA or 
concomitant therapy for another disorder [1, 2]. In the CHER-
ISH trial, back pain and headache occurred in up to one-third 
of children who underwent lumbar puncture, consistent with 
the incidence reported in literature. Serious AEs occurred in 
17% of the patients treated with nusinersen and in 29% in the 
control group. No child discontinued treatment or was with-
drawn from the trial because of an AE [1]. In the ENDEAR 
trial, serious AEs occurred in 76% vs. 95% of, respectively, 
the intervention and control group. Sixteen percent of subjects 
treated with nusinersen vs. 39% of patients who underwent the 
sham-procedure had an AE leading to discontinuation of the 
trial, and all these AEs had fatal outcomes. The most common 
AE with fatal outcome was a respiratory disorder, plausibly 
linked to SMA [2]. The Finkel et al. and Chiriboga et al. trials 
reported good tolerability and no safety concerns [3, 4]. Over-
all, the most commonly reported AEs were possibly related to 
the lumbar puncture, namely backache, headache and vomit-
ing [2, 4].
Discussion
Recent discovery of nusinersen provides hope for optimiz-
ing treatment in patients with SMA. So far, the literature on 
efficacy is scarce. In this review four papers were witheld, 
including two RCTs. Because of heterogeneity in design, 
population and outcome measures, no meta-analysis could 
be performed. Due to different definitions of response, this 
also hinders comparison of outcomes between trials. For 
example, the ENDEAR trial [2] did not include voluntary 
grasp in the HINE-2 assessment because none of the incre-
mental changes in this motor function require movement 
against gravity and voluntary grasp is more developmen-
tally based. This category was included in the assessment 
of HINE-2 in Finkel et al. [3].
Risk of bias analysis is shown in Fig. 2. Inherent to the 
open-label design there is high risk for selection, perfor-
mance and detection bias in the open-label trials [3, 4]. 
There is an unclear risk of attrition bias in the RCTs because 
of early termination of these trials [1, 2]. In Finkel et al., 
results from an interim analysis are given with no important 
missing data at the time of this analysis [3].
Significant and meaningful improvement in motor func-
tion and achievement of development of MM are seen in 
infants with SMA type 1 treated with intrathecal nusinersen 
12 mg EqD (I, high). Significant and meaningful improve-
ment in motor function and achievement of development of 
MM are seen in children with later-onset SMA treated with 
intrathecal nusinersen 12 mg (I, moderate). Though most 
of information came from an RCT [2], quality of recom-
mendation was judged to be moderate because of impreci-
sion due to appreciable benefit that warranted downgrading 
because of relative risk increase greater than 25% (Tables 
S3.2, S3.3, S3.14) and a CI containing no meaningful effect 
(Table S3.1). Survival and event-free survival are signifi-
cantly increased in infants with SMA type 1 treated with 
intrathecal nusinersen 12 mg EqD (I, moderate). Though 
most of information came from an RCT [2], quality of 
recommendation was judged to be moderate because of 
imprecision due to appreciable benefit that warranted down-
grading because of relative risk increase greater than 25% 
(Tables S3.9, S3.10, S3.15) and a CI containing inconsistent 
effects (Table S3.11). Evidence from the included non-RCTs 
[3, 4] was judged to be of very low quality and this because 
of imprecision due to the low number of participants.
A similar search was also performed by the Brazilian 
Medical Association [28]. By grading the level of evidence, 
they considered major inconsistency in the CHERISH trial 
because of conflicting results with improvement in the motor 
function in HFMSE and Revised Upper Limb Module Test 
(RULM) scores, but no differences in new WHO milestones. 
RULM and HFMSE are broader scales with different grades 
per item, and RULM is used to investigate upper limb func-
tion. For example, a maximal gain in rolling from prone to 
supine and/or lifting the head from prone leads to a signifi-
cant improvement in HFMSE, but does not alter develop-
ment of WHO MM. The same consideration can be made for 
the RULM scale. Both scales are validated for their use in 
SMA outcome measurement, whereas development of WHO 
MM not [38–41]. For this reason, we did not consider it an 
inconsistent finding, but it stipulates the need for the use 
of validated and similar outcome measurements in different 
trials, also with the use of the same definitions of ‘response.’
Limitations
Although several statements are level I recommendations, 
we think these findings should be scrutinized. Both RCTs 
were terminated early because the primary endpoint at the 
pre-specified interim analysis was reached and found statisti-
cally significant. A multiple-imputation method to account 
for missing data was used and included 54 (35:19) patients 
in the CHERISH trial. In the CHERISH trial, a sample size 
of 117 patients was estimated to give the trial at least 90% 
power to detect a mean difference of three points in HFMSE 
score. In the final analysis, complete observational data were 
available for 100 patients. The data imputation method was 
used to include 126 patients in total. Because of the lack of 
observational data, the real effect size of treatment is unclear. 
Based on statistical considerations, significance of the pri-
mary endpoints was not evaluated in the final analysis in 
both trials, and using a hierarchical strategy no significance 
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analyses were performed on all secondary endpoints [1, 2]. 
Because of strict inclusion criteria, the investigated popula-
tion might be younger and more homogenous and therefore 
not representative for the overall group of SMA patients [1]. 
Limitations of the non-RCTs [3, 4] are, besides the study 
design, the small number of included patients and relatively 
short duration of follow-up [3, 4].
Data on differentiation in age at death or permanent venti-
lation, compared to a historical cohort [37], should be inter-
preted cautiously because of this relatively small open-label 
design, and we were not able to compare baseline character-
istics because of insufficient information [3]. Possibly there 
was a later age at onset of symptoms and of diagnosis as well 
as more patients receiving nutritional support in the histori-
cal cohort [3, 37]. In both cohorts, the SMA standard of care 
guidelines published in 2007 were used [42]. The provided 
standard of care is related to the outcome of SMA patients 
[43, 44]. Enrollment of patients in the historical cohort was 
between May 2005 and April 2007 [37].
This review has several limitations. As a loading dose 
for intrathecal nusinersen was required in the previous 
studies and because of long half-life time of the drug, one 
should consider a minimum follow-up length, which was 
not pre-specified in our search strategy. Though an exact age 
category was not pre-specified, a younger population was 
expected because of the natural history of the disease. We 
did not include trial registries, expert opinions or searched 
gray literature. The search, data extraction and evaluation of 
the included trials were only performed by the first author.
Impact of key findings
There is level I evidence for recommendation of intrathecal 
nusinersen 12 mg or 12 mg EqD in patients with early- and 
later-onset SMA to obtain improvement in motor function 
and to develop MM. There is also level I evidence that 
this treatment prolongs event-free survival and survival 
in patients with SMA type 1. We suggest that nusinersen 
should be administered in patients with early- and later-
onset SMA as early as diagnosis is sure. This emphasizes the 
importance for early diagnosis. As cost price is high, in Bel-
gium 88,298 euros per dose of 12 mg, in the USA $125,000 
[45], this challenges health institutions and insurance com-
panies. Currently, there is insufficient evidence of efficacy 
in SMA types 3 and 4, or start of treatment in adults. The 
clinical spectrum of patients with SMA is also broader than 
that of the included patients in the studies. Therefore, there 
is need for studies with broader inclusion criteria to cover 
the more heterogeneous population, also including more dif-
ferent SMA types and age categories, including adults. The 
financial burden should be further clarified. Because of the 
importance of early treatment, awareness of SMA is needed 
at birth.
Conclusions
Treatment with intrathecal nusinersen in patients with 
early- and later-onset SMA results in significant and clini-
cally meaningful improvement in motor function (I, high in 
SMA type 1, moderate in later-onset SMA)—but does not 
restore age-appropriate function—with better improvement 
if started earlier in disease course and results in prolonged 
event-free survival and survival in patients with SMA type 1 
(I, moderate). Intrathecal nusinersen has an acceptable safety 
and tolerability profile. Further trials regarding long-term 
effects and safety aspects as well as trials including broader 
SMA and age categories are required and ongoing.
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